Cargando…
Novel Drugs and Radiotherapy in Relapsed Lymphomas: Abscopal Response and Beyond
SIMPLE SUMMARY: Relapsed or refractory (r/r) lymphomas represent hard-to-treat cancers with dismal prognoses. Over the past few years, immune checkpoint inhibitors targeting programmed cell death protein 1 (PD-1) and programmed cell death ligand 1 (PD-L1) have changed treatment paradigms in many mal...
Autores principales: | Perrone, Salvatore, Lopedote, Paolo, De Sanctis, Vitaliana, Iamundo De Cumis, Ilenia, Pulsoni, Alessandro, Strati, Paolo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216471/ https://www.ncbi.nlm.nih.gov/pubmed/37345088 http://dx.doi.org/10.3390/cancers15102751 |
Ejemplares similares
-
Targeted Treatment of Relapsed or Refractory Follicular Lymphoma: Focus on the Therapeutic Potential of Mosunetuzumab
por: Lopedote, Paolo, et al.
Publicado: (2023) -
Beyond Abscopal Effect: A Meta-Analysis of Immune Checkpoint Inhibitors and Radiotherapy in Advanced Non-Small Cell Lung Cancer
por: Fiorica, Francesco, et al.
Publicado: (2021) -
Infectious Aetiology of Marginal Zone Lymphoma and Role of Anti-Infective Therapy
por: Perrone, Salvatore, et al.
Publicado: (2016) -
Enhancing the Bystander and Abscopal Effects to Improve Radiotherapy Outcomes
por: Farias, Virgínea de Araújo, et al.
Publicado: (2020) -
Intensity modulated radiotherapy in early stage Hodgkin lymphoma patients: Is it better than three dimensional conformal radiotherapy?
por: De Sanctis, Vitaliana, et al.
Publicado: (2012)